Tag: Pharma
TME Pharma announces a capital increase of 2.7 million euros
(AOF) – TME Pharma announced the launch of a 100% guaranteed capital increase of 2.7 million euros through the issue of new shares associated with subscription warrants making it possible…
TME PHARMA LAUNCHES A FULLY GUARANTEED CAPITAL INCREASE OF €2.7 M WITH PREFERENTIAL SUBSCRIPTION RIGHTS (DPS) FOR SHARES ASSOCIATED WITH SUBSCRIPTION VOUCHERS (ABSA) AND ANNOUNCES THE PURCHASE OF PART OF ITS CONVERTIBLE DEBT – 24/11 /2023 at 6:15 p.m.
Attention ! This investment does not fall within the scope of AMF control. No license and no prospectus is required for this activityThis information is not intended for residents of…
TME Pharma announces a capital increase of 2.7 million euros – 11/24/2023 at 6:16 p.m.
(AOF) – TME Pharma announced the launch of a 100% guaranteed capital increase of 2.7 million euros through the issue of new shares associated with subscription warrants making it possible…
Abionyx Pharma announces positive results in ophthalmology – 11/21/2023 at 09:38
(AOF) – Abionyx Pharma announces new positive results in ophthalmology in the first class of biomedicines from CER-001 for the treatment of ocular pathologies. This biotech specialist in innovative therapies…
TME PHARMA ANNOUNCES THE PRESENTATION OF ADDITIONAL DATA ON COMBINATION TREATMENT OF NOX-A12 IN BRAIN CANCER AT THE SNO 2023 ANNUAL MEETING – 11/18/2023 at 08:00
TME PHARMA ANNOUNCES PRESENTATION OF ADDITIONAL DATA ON COMBINATION TREATMENT OF NOX-A12 IN BRAIN CANCER AT SNO 2023 ANNUAL MEETING • Substantial improvement in survival and progression-free survival in NOX-A12…
Innate Pharma: a lower tone
By Claude Leguilloux Published on 11/15/2023 at 2:28 p.m. (Boursier.com) — Innate Pharma fell 0.4% to 2.25 euros…
Abionyx Pharma: 3.59 million euros in turnover over nine months
(AOF) – Abionyx Pharma announces consolidated turnover for the first nine months of the year of 3.59 million euros “after elimination of intra-group operations”. The new generation biotech indicates that…
Innate Pharma: cash flow horizon in the 2nd half of 2025
(CercleFinance.com) – The biopharmaceutical company Innate Pharma displays cash, cash equivalents and financial assets amounting to 121.9 million euros as of September 30, 2023, with an expected horizon during the…
MaaT Pharma: treatment of a first patient in the randomized Phase 2b clinical trial evaluating MaaT033 in patients receiving allo-HSCT
By Claude Leguilloux Published on 06/11/2023 at 08:01 a.m. Photo credit © Boursier.com (Boursier.com) — MaaT Pharmaa late-stage…
MaaT Pharma: ambitious?
By Claude Leguilloux Published on 06/11/2023 at 09:31 a.m. MaaT Pharma climbs 2.6% to 7.80 euros, as the advanced clinical stage biotechnology company, leader…
MaaT Pharma: presentation of two posters for MaaT013 and MaaT033 at the next ASH conference
By Hector Chaunu Published on 02/11/2023 at 6:22 p.m. Photo credit © ChaunuPictures (Boursier.com) — MaaT Pharmaa late-stage…
Innate Pharma: three results presented at the ASH congress in December
(AOF) – Innate Pharma (+4% to 0.028 euros) announces today that several abstracts, including an oral presentation, have been selected for the 65th annual meeting of the ASH (American Society…